Lodelcizumab

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameLodelcizumab
Drug Alias NameAnti-PCSK9 monoclonal antibody (Novartis)抗PCSK9单克隆抗体 - 诺华NVP-LGT-209LGT-209
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionProprotein convertase subtilisin kexin type 9 inhibitors
TargetsProprotein convertase subtilisin kexin type 9
Therapy Area/IndicationsHypercholesterolemia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNovartis Pharma Ag
Active IndicationsN/A
Inactive IndicationsHypercholesterolemia

Other Information

ATC CodeN/A
Related LinksN/A